Bargain Monday: Extreme Fear, 40% Drawdowns, and Insider Buying in the Wreckage

This Week's Setup

Extreme fear is sitting at 21/100, the kind of panic-driven selloff that historically unlocks asymmetry for fundamentals-first buyers. The top five names this week are trading at an average 52-week drawdown of 21%, yet each carries an earnings yield well above where the 10-year Treasury was last quoted. When sentiment sours this hard, price dislocations run ahead of earnings reality—and that's the setup here.

---

The Five Names

1. First Solar, Inc. (FSLR)

Stock Pixie Score 10.0/10 (a composite of valuation, income quality, and price recovery signals) | P/E 14.23 | ROIC 22.2% | 52-week drawdown -29.4%

FSLR is trading at a 7.0% earnings yield against a 2.8% yield spread—a 410bp premium—while revenue grew 24% YoY and gross margin stands at 40.6%. The company is generating an ROIC north of 22% in a sector notorious for capital intensity, and the EV/EBITDA of 8.95 prices it like cyclical solar, not a margin-rich manufacturing franchise.

Free cash flow data is missing from the screener output, which limits visibility into whether capital intensity is spiking or if working capital is masking conversion quality. The 29.4% drawdown puts this in "strong entry" territory by drawdown zone logic, but without FCF yield confirmation, you're relying on accrual earnings and analyst optimism.

Insider activity flags net selling over six months—Verma, Theurer, and Gloeckler all filed Form 4s in early March—though the selling represents only 1.6% of insider holdings. Guggenheim just reset the price target to $269 from $312 while maintaining a Buy, and the consensus target of $257 implies 27% upside from here.

The debt-to-equity ratio of 0.40 is manageable, but solar manufacturers live and die by subsidy regimes and polysilicon costs—two variables that can crater margins faster than ROIC models suggest.

---

2. Emergent BioSolutions Inc. (EBS)

Stock Pixie Score 9.3/10 | P/E 8.98 | Earnings yield 11.1% | 52-week drawdown -40.6%

An 11.1% earnings yield at a P/E under 9 is statistical extremity—EBS is priced for permanent impairment, yet gross margin sits at 53.7% and ROIC at 15.8%. The yield spread of 6.9% over the 10-year is wider than you'll find in most value screens this cycle, and EV/EBITDA of 3.89 implies the market is discounting the entire business to near-liquidation multiples.

Revenue fell 30% YoY, and debt-to-equity is 1.52—this is a leveraged biodefense contractor in a demand trough. The shareholder yield of 5.7% is being funded by asset sales or buybacks, not organic FCF generation, and the trend slope over one year is barely positive at 0.36%.

Insiders have been net sellers over six months—48,191 shares dumped—but recent Form 4 filings from Glessner, Perl, and Papa in early March signal at least some activity around the current price. The appointment of John D. Fowler, Jr. to the board was announced this month, a governance refresh that sometimes precedes strategic pivots or sale processes.

Mpox headlines are lifting the sector, but biodefense revenue is binary and politically volatile—one budget cut or contract delay erases the entire thesis, and the -30% revenue print is a reminder that this isn't a growth story masquerading as value.

---

3. Newmont Corporation (NEM)

Stock Pixie Score 9.1/10 | P/E 18.08 | ROIC 36.9% | 52-week drawdown -14.5%

NEM is posting a 36.9% ROIC with 53.2% gross margin and 21.3% revenue growth YoY—these are best-in-class operating metrics for a diversified miner. The earnings yield of 5.5% against a 1.3% yield spread translates to a 420bp premium, and the 14.5% drawdown is shallow enough that you're not buying wreckage, just a temporary de-rating in a risk-off tape.

Insiders have been net buyers over the last six months—30,406 shares accumulated—and the buy-to-sell ratio tilts 2.2% to 1.2%. Wexler, Hardy, and Rodgers all filed Form 4s in late February and early March, with transactions clustered around current levels.

Analyst consensus sits at $139.91, implying 21.3% upside, and the shareholder yield of 1.8% is being returned via dividends in a sector where most peers are levered to buybacks. Newmont is the largest gold miner by market cap, so it moves on macro gold sentiment, not idiosyncratic catalysts.

At a P/E of 18, you're paying a premium multiple for a commodity producer—gold rallies can justify it, but if real rates rise or the dollar strengthens, the valuation cushion disappears fast. The debt-to-equity of 0.68 is reasonable but not pristine, and EV/EBITDA of 9.17 is elevated for the sector.

---

4. Exelixis, Inc. (EXEL)

Stock Pixie Score 8.8/10 | P/E 14.97 | ROIC 68.5% | 52-week drawdown -16.1%

EXEL is printing a 68.5% ROIC with a 96.4% gross margin—these are monopoly-like economics in oncology, and the 6.7% earnings yield with a 2.5% yield spread gives you a 420bp premium over Treasuries. Revenue growth of 7% YoY is modest, but the shareholder yield of 8.5% signals aggressive capital return in the form of buybacks, and the EV/EBITDA of 10.70 is reasonable for a profitable biotech.

Insiders have been aggressive net buyers—2.16 million shares accumulated over six months, with an 80.5% buy ratio versus 20% sell. Aftab, Oliver, and Eckhardt all filed Form 4s in mid-February, and the clustering of buys at this price level is one of the strongest insider signals in the entire screen.

Exelixis just beat earnings and expanded the CABOMETYX label; the PDUFA date for zanzalintinib in CRC is December 2026, a binary catalyst on the calendar. Leerink and Barclays both hosted management recently, and the Street is debating sequencing strategies for RCC—this is an active, analyst-covered name, not a forgotten value trap.

The 12.5% implied upside to the $46.83 analyst target is the narrowest on this list, and biotech is a binary sector—one FDA setback or competitive encroachment in RCC and the re-rating thesis evaporates. Debt-to-equity of 0.32 is low, but you're still dependent on pipeline execution.

---

5. CNX Resources Corporation (CNX)

Stock Pixie Score 8.2/10 | P/E 10.19 | Earnings yield 9.8% | 52-week drawdown -7.0%

CNX is trading at a 9.8% earnings yield with a 5.6% yield spread—a 540bp premium over the 10-year—and revenue surged 48.9% YoY, the highest growth rate in this week's screen. The shareholder yield of 9.1% is being returned aggressively, and the EV/EBITDA of 5.66 is the second-lowest multiple on the list, pricing CNX like a distressed E&P despite the earnings momentum.

The analyst target of $37.23 implies -8.2% downside from the current price of $40.56, a rare setup where the Street is more bearish than the screener. The debt-to-equity of 1.10 is elevated for a gas producer in a volatile commodity environment, and the 7% drawdown signals the market hasn't punished this yet—you're not buying deep dislocation, just moderate compression.

Insider activity is net positive—377,087 shares bought over six months—and Bernard Lanigan Jr. filed a Form 4 in late February. The buy-to-sell ratio of 6.8% to 0.7% is lopsided in favor of accumulation, but the absolute dollar amounts aren't disclosed in the data provided.

Natural gas pricing is the entire thesis—CNX is a pure-play Appalachian gas producer, and if Henry Hub rolls over or LNG export momentum stalls, the 48.9% revenue growth reverses into contraction. The negative analyst target spread is the loudest risk flag here.

---

What to Watch

• FSLR earnings reaction: Next quarterly print will show whether capital intensity is spiking or if FCF conversion is improving—watch for guidance on polysilicon costs and IRA subsidy realization.
• EBS contract announcements: Biodefense revenue is lumpy; any new BARDA or HHS contract award will move the stock faster than earnings.
• Newmont gold price sensitivity: If the 10-year yield rises and the dollar strengthens, NEM's premium multiple compresses—track real rates, not just spot gold.
• EXEL December PDUFA: The zanzalintinib colorectal cancer decision is a binary catalyst; positioning ahead of FDA action is the trade, not the long-term hold.
• CNX natural gas forward curve: Henry Hub pricing and LNG export capacity will dictate whether the 48.9% revenue growth is sustainable or a one-year spike.

---

Go Deeper

The value screener hunts for statistically cheap stocks with earnings quality and recent price dislocations—low P/E, high earnings yield, strong ROIC, and drawdowns that create entry points.

What the top 5 don't show: the next 45 ranked names, sector filters, custom yield spread thresholds, and real-time insider transaction tracking. Pro subscribers see the full pipeline with sortable columns and alert triggers.

See all value picks →

---

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that combines valuation (P/E, P/B, earnings yield), income quality (ROIC, gross margin, FCF conversion), and price recovery signals (drawdown depth, trend slope, analyst target spreads). It's designed to surface statistically cheap stocks with operational strength and recent price dislocations—the intersection where fundamentals and sentiment diverge. A score above 8 is a strong signal; 6–7.9 is solid; below 6 means the caveats outweigh the setup. The weights are proprietary, but the philosophy is transparent: we rank what the data shows, not what narratives suggest.

---

The Fine Print

This is not financial advice—it's a screener output and analysis for informational purposes. Stock Pixie is a research tool; you are responsible for your own investment decisions. Do your own due diligence before acting on any name discussed here.

---